Literature DB >> 25454978

Ablation of 5-lipoxygenase mitigates pancreatic lesion development.

Lawrence M Knab1, Michelle Schultz2, Daniel R Principe3, Windel E Mascarinas2, Elias Gounaris3, Hidayatullah G Munshi4, Paul J Grippo2, David J Bentrem5.   

Abstract

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC), which continues to have a dismal prognosis, is associated with a pronounced fibroinflammatory response. Inflammation in vivo can be mediated by 5-lipoxygenase (5LO), an enzyme that converts omega-6 fatty acids (FA) to eicosanoids, including leukotriene B4 (LTB4). We have previously shown that diets rich in omega-6 FA increase pancreatic lesions and mast cell infiltration in EL-Kras mice. In this study, we evaluated the role of 5LO in generating higher levels of LTB4 from human cells and in mediating lesion development and mast cell infiltration in EL-Kras mice.
MATERIALS AND METHODS: Human pancreatic ductal epithelial and cancer cells were treated with omega-6 FA in vitro. EL-Kras mice lacking 5LO (EL-Kras/5LO(-/-)) mice were generated and fed standard chow or omega-6 FA diets. Pancreatic lesion frequency and mast cell infiltration were compared with EL-Kras/5LO(+/+) mice. Human PDAC tumors were evaluated for 5LO expression and mast cells.
RESULTS: Human pancreatic ductal epithelial and pancreatic cancer cells treated with omega-6 FA generated increased LTB4 levels in vitro. EL-Kras/5LO(-/-) mice developed fewer pancreatic lesions and had decreased mast cell infiltration when compared with EL-Kras/5LO(+/+) mice. Human PDAC tumors with increased 5LO expression demonstrate increased mast cell infiltration. Additionally, diets rich in omega-6 FA failed to increase pancreatic lesion development and mast cell infiltration in EL-Kras/5LO(-/-) mice.
CONCLUSIONS: The expansion of mutant Kras-induced lesions via omega-6 FA is dependent on 5LO, and 5LO functions downstream of mutant Kras to mediate inflammation, suggesting that 5LO may be a potential chemopreventive and therapeutic target in pancreatic cancer.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  5-Lipoxygenase; Inflammation; Omega-6 fatty acids; Pancreatic cancer

Mesh:

Substances:

Year:  2014        PMID: 25454978      PMCID: PMC4843112          DOI: 10.1016/j.jss.2014.10.021

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

1.  Characterising cis-regulatory variation in the transcriptome of histologically normal and tumour-derived pancreatic tissues.

Authors:  Mingfeng Zhang; Soren Lykke-Andersen; Bin Zhu; Wenming Xiao; Jason W Hoskins; Xijun Zhang; Lauren M Rost; Irene Collins; Martijn van de Bunt; Jinping Jia; Hemang Parikh; Tongwu Zhang; Lei Song; Ashley Jermusyk; Charles C Chung; Bin Zhu; Weiyin Zhou; Gail L Matters; Robert C Kurtz; Meredith Yeager; Torben Heick Jensen; Kevin M Brown; Halit Ongen; William R Bamlet; Bradley A Murray; Mark I McCarthy; Stephen J Chanock; Nilanjan Chatterjee; Brian M Wolpin; Jill P Smith; Sara H Olson; Gloria M Petersen; Jianxin Shi; Laufey Amundadottir
Journal:  Gut       Date:  2017-06-20       Impact factor: 23.059

2.  Modeling of cancer-related body-wide effects identifies LTB4 as a diagnostic biomarker for pancreatic cancer.

Authors:  Shu-Heng Jiang; Dejun Liu; Li-Peng Hu; Shan Zhang; Yanqiu Yu; Yong-Wei Sun; Jianguang Ji; Zhi-Gang Zhang
Journal:  EBioMedicine       Date:  2022-05-10       Impact factor: 11.205

Review 3.  The yin and yang of leukotriene B4 mediated inflammation in cancer.

Authors:  Venkatakrishna R Jala; Sobha R Bodduluri; Shuchismita R Satpathy; Zinal Chheda; Rajesh K Sharma; Bodduluri Haribabu
Journal:  Semin Immunol       Date:  2017-10-02       Impact factor: 11.130

Review 4.  Cross-Talk between Cancer Cells and the Tumour Microenvironment: The Role of the 5-Lipoxygenase Pathway.

Authors:  Gillian Y Moore; Graham P Pidgeon
Journal:  Int J Mol Sci       Date:  2017-01-24       Impact factor: 5.923

Review 5.  Leukotrienes in Tumor-Associated Inflammation.

Authors:  Wen Tian; Xinguo Jiang; Dongeon Kim; Torrey Guan; Mark R Nicolls; Stanley G Rockson
Journal:  Front Pharmacol       Date:  2020-08-19       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.